⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMEA News
Biomea Fusion, Inc. Common Stock
Form 8-K
sec.gov
BMEA
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
globenewswire.com
BMEA
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
globenewswire.com
BMEA
Form 8-K
sec.gov
BMEA
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
globenewswire.com
BMEA
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
globenewswire.com
BMEA
Form 8-K
sec.gov
BMEA
Biomea Fusion to Participate at Upcoming Investor Conferences
globenewswire.com
BMEA
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
globenewswire.com
BMEA
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
BMEA